ECOG- GI Studies Patient Education Materials Available

Patient Education Materials Available for Colorectal Clinical Trials
E4203, E5202, and E5204/R-04

We are pleased to provide you with this webpage, which offers detailed information on the E4203, E5202, and E5204/R-04 Colorectal Clinical Trials. Within this page you will various resources on these three clinical trials.

These materials will provide you with the necessary tools to:

Review the rationale, schema, and eligibility for each of the trials

Discuss the issue of risk

Review key points of discussion when talking to patients

We hope you find this webpage informative and helpful as you treat your patients with colorectal cancer.

Should you have any questions or wish to receive additional information regarding these state-of-the-art trials, please visit Introduction to ECOG or Contact ECOG.

E5202 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

E5204/R-04 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation

E4203 - Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer


ECOG Introduction to ECOG Clinical Trials Guide For Cancer Patients What is a clinical trial? Why participate? Does insurance cover costs? What if I change my mind? How can I join a clinical trial? ECOG's active protocols Patient Information Selenium E5597 GI Studies E4203,E5202,E5204 Melanoma E2603 Prostate CHAARTED E3805 Cancer in Siblings E1Y97 Non-Hodgkins Lymphoma E4402 Breast Cancer PACCT1: TAILORx Informational Videos Trial Summary Results Trial Monitoring ECOG Data Monitoring Committee ECOG Institutions Institutions by state Alphabetical listing Joining ECOG Publications Publications bibliography Announcements TAILORx Webinar Information NCI Press Release: Bevacizumab... Job Openings Future ECOG Meeting Dates Researcher Advocate Partners Investigator Awards NCI-VA Initiative Scales and Criteria ECOG Performance Status Common Toxicity Criteria Cancer Information Breast Cancer Video Colon Cancer Video Cancer Survivor Publications Releasing Results Guidelines Other Cancer Sites ECOG Main Institutions' Sites Other Cooperative Groups Advocates/Support Groups ECOG HOME PAGE ECOG MEMBERS INFORMATION (password required) GLOSSARY SEARCH CONTACT INFORMATION DISCLAIMER			Patient Education Materials Available for Colorectal Clinical Trials E4203, E5202, and E5204/R-04 We are pleased to provide you with this webpage, which offers detailed information on the E4203, E5202, and E5204/R-04 Colorectal Clinical Trials. Within this page you will various resources on these three clinical trials. These materials will provide you with the necessary tools to: Review the rationale, schema, and eligibility for each of the trials Discuss the issue of risk Review key points of discussion when talking to patients Additionally, we have included a document providing background and rationale for enrollment in E5202 for your patients who have been diagnosed with stage II colorectal cancer. We hope you find this webpage informative and helpful as you treat your patients with colorectal cancer. Should you have any questions or wish to receive additional information regarding these state-of-the-art trials, please visit Introduction to ECOG or Contact ECOG. E5202 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers E5202 Background Slide Presentation Physician Discussion Sheet on E5202 Patient Handout for Physician Discussion Sheet on E5202 E5202 Pocket-Sized Reference Card E5202 Site Fast Facts E5202 Patient FAQ E5204/R-04 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation E5204 Background Slide Presentation E5204 Pocket-Sized Reference Card E5204 Patient FAQ E4203 - Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer E4203 Pocket-Sized Reference Card E4203 Patient FAQ Next topic How to contact ECOG All contents copyright © 2001 Eastern Cooperative Oncology Group. All rights reserved. Revised: May 29, 2008

Patient Education Materials Available for Colorectal Clinical Trials E4203, E5202, and E5204/R-04

Patient Education Materials Available for Colorectal Clinical Trials
E4203, E5202, and E5204/R-04